BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YESAFILI (aflibercept-jbvf) is a biosimilar fusion protein approved in May 2024 by Biocon, designed as a follow-on to reference aflibercept products. As a VEGF pathway inhibitor, it targets vascular endothelial growth factor to treat retinal and other vascular diseases. The fusion modality enables dual binding capability for enhanced therapeutic targeting.
Growth
As a recently launched biosimilar in the growth phase with minimal competitive pressure data (30% cited), the brand team is likely expanding to capture market share in the established aflibercept category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Biocon is hiring 2 roles related to this product
Worked on YESAFILI at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.